Green Biologics
closedRenewable chemicals naturally designed to deliver the performance that adds value to everyday products.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
N/A | Grant | ||
| Total Funding | 000k | ||
| GBP | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 1685 % | (75 %) | (79 %) | - | (94 %) | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (27 %) | (145 %) | (730 %) | (2306 %) | 5316 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (45 %) | (205 %) | (1177 %) | (2819 %) | (469 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 15 % | 76 % | 81 % | 70 % | - | - | - |
Source: Company filings or news article
Biocleave specializes in the production of high-purity, active recombinant proteins using non-pathogenic clostridia as an endotoxin-free expression host. The company operates in the biotechnology sector, serving clients in the pharmaceutical, research, and industrial biotechnology markets. Biocleave's business model revolves around leveraging its extensive strain collection and over 15 years of expertise in engineering, adapting, and fermenting clostridia to push the boundaries of protein expression. By utilizing endogenous CRISPR Cas technology, Biocleave is able to engineer these microbes for novel applications, providing a unique value proposition to its clients. The company generates revenue through the sale of its recombinant proteins and related services, catering to scientists and researchers who require high-quality, endotoxin-free proteins for their work.
Keywords: recombinant proteins, non-pathogenic clostridia, endotoxin-free, CRISPR Cas, biotechnology, pharmaceutical, research, industrial, protein expression, fermentation.